Home Alzheimer’s Disease Venetoclax with Azacytidine Improved Overall Survival for Patients with AML

Venetoclax with Azacytidine Improved Overall Survival for Patients with AML

Venetoclax (Venclexta) in combination with azacytidine met its dual primary endpoints of overall survival and composite complete remission rate in a phase III VIALE-A study, according to a Genentech press release.

The combination showed a statistically significant improvement in overall survival for people with previously untreated acute myeloid leukemia, who were also ineligible for intensive induction chemotherapy. The results were significant compared to treatment with azacytidine, a hypomethylating agent, alone.

“Acute myeloid leukemia remains a challenging blood cancer, with particularly low median survival rates in patients who cannot tolerate intensive chemotherapy given their age or underlying health,” Levi Garraway, MD, PhD, chief medical officer and head of global product development said in a press release. “These data validate the benefit that this Venclexta-based…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments